Comprehensive Management of Diabetes and Kidney Disease

Introduction to Management

• The American College of Cardiology and other guideline societies recommend a comprehensive treatment strategy focusing on glycemic control, blood pressure management, albuminuria reduction, and addressing diabetic retinopathy to reduce risks of kidney disease progression and cardiovascular complications in patients with diabetes and kidney disease 1, 2

Glycemic Control

• The European Society of Cardiology recommends implementing intensive glycemic control targeting HbA1c <7.0% to decrease microvascular complications in patients with diabetes 3
• For patients with type 2 diabetes and eGFR of 56 ml/min/1.73m², the American Diabetes Association recommends starting or continuing metformin (can be used with eGFR ≥30 ml/min/1.73m²) 4
• The American Diabetes Association also recommends adding SGLT2 inhibitor as first-line therapy (can be initiated with eGFR ≥20 ml/min/1.73m²) for both glycemic control and renoprotection in patients with type 2 diabetes and kidney disease 4, 5

Blood Pressure Management

• The American Heart Association recommends initiating or optimizing ACE inhibitor or ARB therapy and titrating to the highest tolerated dose, as patients with hypertension and albuminuria benefit from this treatment 6, 3
• The American Heart Association recommends targeting blood pressure <130/80 mmHg in patients with diabetes and kidney disease 3, 7
• The National Kidney Foundation recommends monitoring serum creatinine and potassium within 2-4 weeks after starting or changing dose of ACEi/ARB in patients with kidney disease 8

Management of Albuminuria and CKD

• The National Kidney Foundation recommends maximizing RAS blockade with ACEi/ARB as the cornerstone of therapy for albuminuria in patients with kidney disease 6, 8
• The European Society of Cardiology strongly recommends SGLT2 inhibitor for renoprotection in patients with kidney disease and albuminuria 5
• The American Heart Association recommends reducing dietary sodium intake to <2.3 g/day to optimize effectiveness of antihypertensive medications in patients with kidney disease 9

Management of Diabetic Retinopathy

• The American Academy of Pediatrics recommends referring patients to an ophthalmologist for management of moderate NPDR 10
• The American Academy of Pediatrics recommends annual dilated eye examinations by an ophthalmologist for patients with diabetes 10
• The European Society of Cardiology recommends tight glycemic and blood pressure control to prevent progression of retinopathy in patients with diabetes 3

Lipid Management

• The American College of Cardiology recommends starting or continuing statin therapy for cardiovascular risk reduction in patients with diabetes and kidney disease 1, 2
• The American College of Cardiology recommends targeting LDL-C based on cardiovascular risk assessment in patients with diabetes and kidney disease 9

Lifestyle Modifications

• The European Association for the Study of Diabetes recommends providing structured education on diabetes self-management for patients with diabetes 3
• The American Heart Association recommends moderate-intensity physical activity for at least 150 minutes per week for patients with diabetes and kidney disease 4
• The American Heart Association recommends dietary modifications including sodium restriction (<2.3 g/day), moderate protein intake, and appropriate carbohydrate management for patients with diabetes and kidney disease 9, 4

Follow-up and Monitoring

• The National Kidney Foundation recommends regular risk factor reassessment every 3-6 months for patients with diabetes and kidney disease 1, 2
• The American Heart Association recommends monitoring blood pressure, glycemic control, kidney function, and albuminuria in patients with diabetes and kidney disease 9
• The American Academy of Pediatrics recommends scheduling follow-up eye examination in 6-12 months or sooner if visual symptoms develop for patients with diabetes 10